Cel-Sci - 30 Year Stock Price History | CVM

Historical daily share price chart and data for Cel-Sci since 1991 adjusted for splits. The latest closing stock price for Cel-Sci as of September 24, 2021 is 11.95.
  • The all-time high Cel-Sci stock closing price was 11800.00 on November 07, 1991.
  • The Cel-Sci 52-week high stock price is 40.91, which is 242.3% above the current share price.
  • The Cel-Sci 52-week low stock price is 7.08, which is 40.8% below the current share price.
  • The average Cel-Sci stock price for the last 52 weeks is 15.40.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Cel-Sci Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2021 16.2310 12.0000 27.6400 7.6400 11.9500 2.49%
2020 13.0443 9.0900 17.6000 7.5400 11.6600 27.43%
2019 6.1802 2.8900 9.6000 2.5800 9.1500 218.82%
2018 2.3678 1.8600 4.2600 0.8297 2.8700 51.87%
2017 2.2183 1.7725 3.9750 1.5900 1.8898 12.49%
2016 10.5651 10.0000 15.8750 1.6800 1.6800 -81.84%
2015 17.7444 15.4725 29.7500 9.2400 9.2500 -36.32%
2014 25.5468 16.2500 45.7500 13.5000 14.5250 -1.84%
2013 50.2212 69.3750 73.7500 14.1950 14.7975 -78.08%
2012 93.9612 75.0000 147.5000 67.5000 67.5000 -6.86%
2011 127.6821 206.6250 207.8750 68.7500 72.4750 -64.69%
2010 160.9908 230.0000 257.5000 112.5000 205.2500 -8.78%
2009 159.6703 77.5000 482.5000 37.5000 225.0000 215.79%
2008 134.3996 132.4750 175.0000 45.0000 71.2500 -44.11%
2007 172.5876 145.0000 240.0000 125.0000 127.4750 -8.95%
2006 189.1336 122.5250 432.5000 122.5000 140.0000 14.29%
2005 145.2032 157.5000 240.0000 112.5000 122.5000 -18.33%
2004 208.7817 287.5000 345.0000 117.5000 150.0000 -43.40%
2003 171.1012 52.5000 420.0000 42.5000 265.0000 404.76%
2002 95.8284 237.5000 292.5000 45.0000 52.5000 -77.89%
2001 356.6734 440.0000 712.5000 197.5000 237.5000 -36.67%
2000 885.1696 577.5000 3000.0000 265.0000 375.0000 -35.06%
1999 576.5972 407.5000 952.5000 407.5000 577.5000 32.00%
1998 972.5595 1547.5000 1595.0000 390.0000 437.5000 -73.56%
1997 1257.4605 1092.5000 2500.0000 717.5000 1655.0000 55.76%
1996 1513.7697 845.0000 3235.0000 672.5000 1062.5000 18.38%
1995 1047.6687 1250.0000 1875.0000 610.0000 897.5000 -12.44%
1994 2256.8452 4075.0000 4450.0000 850.0000 1025.0000 -71.53%
1993 3761.4625 4525.0000 4925.0000 3050.0000 3600.0000 -24.61%
1992 5109.4488 7275.0000 9150.0000 2825.0000 4775.0000 -40.13%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.527B $0.001B
CEL-SCI CORP. was formed to acquire and finance research and development of natural human interleukin-2 (``IL-2``) and lymphokine-related products and processes using the Co.'s proprietary cell culture technologies. The Co.'s proprietary product is sometimes referred to as MULTIKINEn, or buffy-coat interleukins, which is a combination, or ``cocktail`` of IL-2 and certain lymphokines and cytokines. MULTIKINE is a trade name of Co. Since its inception the focus of the Co.'s product development efforts has been on conducting clinical trials to test its proprietary technologies.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.727B 8.97
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.500B 21.17
Biohaven Pharmaceutical Holding (BHVN) United States $8.865B 0.00
Emergent Biosolutions (EBS) United States $2.891B 6.97
Arcus Biosciences (RCUS) United States $2.641B 0.00
Myovant Sciences (MYOV) United Kingdom $2.145B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.998B 0.00
Zymeworks (ZYME) Canada $1.380B 0.00
Ambrx Biopharma (AMAM) United States $0.521B 0.00
SQZ Biotechnologies (SQZ) United States $0.427B 0.00
Enzo Biochem (ENZ) United States $0.175B 51.71